lanreotide (Autogel formulation)

ApprovedCompleted

0 views this week 0 watching⚡ Active

Interest: 40/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

✓

Phase 3

Approved

Indication / Disease

Neuroendocrine Tumour With Carcinoid Symptoms

Conditions

Neuroendocrine Tumour With Carcinoid Symptoms

Trial Timeline

Jun 1, 2008 → Aug 1, 2010

NCT ID

NCT00681187

About lanreotide (Autogel formulation)

lanreotide (Autogel formulation) is a approved stage product being developed by Ipsen for Neuroendocrine Tumour With Carcinoid Symptoms. The current trial status is completed. This product is registered under clinical trial identifier NCT00681187. Target conditions include Neuroendocrine Tumour With Carcinoid Symptoms.

What happened to similar drugs?

5 of 15 similar drugs in Neuroendocrine Tumour With Carcinoid Symptoms were approved

Approved (5) Terminated (2) Active (9)

🔄Lutetium (177Lu) Oxodotreotide Injection；long-acting Octreotide + long-acting Octreotide.Jiangsu Hengrui MedicinePhase 3

🔄68Ga-DOTATOCJiangsu Hengrui MedicinePhase 3

✅Everolimus (RAD001)NovartisApproved

🔄Everolimus + Everolimus PlaceboNovartisPhase 3

✅Pasireotide + DiazoxideNovartisApproved

🔄[68Ga]Ga-DOTA-TATE + 68Ge/68Ga GeneratorNovartisPhase 3

✅everolimusNovartisApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (10)

NCT ID	Phase	Status	Start	Completion	Indication
NCT02365584	Phase 2	Terminated	Jan 1, 2015	Jan 16, 2018	Intestinal Obstruction
NCT00891371	Phase 2/3	Completed	Jul 1, 2009	Aug 1, 2013	Diarrhea
NCT00842348	Phase 3	Completed	Feb 1, 2009	Dec 1, 2015	Non Functioning Entero-pancreatic Endocrine Tumour
NCT00681187	Approved	Completed	Jun 1, 2008	Aug 1, 2010	Neuroendocrine Tumour With Carcinoid Symptoms
NCT00517491	Phase 2	Withdrawn	May 1, 2008	Dec 1, 2008	Acromegaly
NCT00326469	Phase 2	Completed	May 1, 2006	Nov 1, 2009	Neuroendocrine Tumours
NCT00216398	Approved	Completed	Jun 1, 2004	Jun 22, 2006	Acromegaly
NCT00149188	Approved	Completed	Feb 1, 2004	Aug 24, 2005	Acromegaly
NCT00210457	Phase 3	Completed	Sep 1, 2000	Jul 15, 2002	Acromegaly
NCT00234572	Phase 2/3	Completed	May 1, 2000	Jan 3, 2003	Acromegaly

Competing Products

20 competing products in Neuroendocrine Tumour With Carcinoid Symptoms

See all competitors

Product	Company	Stage	Hype Score
[203Pb]VMT-α-NET + [212Pb]VMT-α-NET	Perspective Therapeutics	Phase 1/2	33
[203Pb]VMT-α-NET	Perspective Therapeutics	Phase 1	27
[212Pb] VMT-α-NET	Perspective Therapeutics	Phase 1	27
Lenvatinib	Eisai	Phase 2	35
Abemaciclib	Eli Lilly	Phase 2	39
Lutetium (177Lu) Oxodotreotide Injection；long-acting Octreotide + long-acting Octreotide.	Jiangsu Hengrui Medicine	Phase 3	47
Famitinib	Jiangsu Hengrui Medicine	Phase 2	27
68Ga-DOTATOC	Jiangsu Hengrui Medicine	Phase 3	47
Olaparib	AstraZeneca	Phase 2	27
Avelumab	Merck	Phase 1/2	32
Pembrolizumab	Merck	Phase 2	27
Lenvatinib + Pembrolizumab + Hyperpolarized 13C-Pyruvate	Merck	Phase 2	42
Pembrolizumab	Merck	Phase 2	35
Pembrolizumab Injection	Merck	Phase 2	27
Carboplatin + Cisplatin + Docetaxel + Etoposide + Pembrolizumab	Merck	Phase 1	33
Avelumab	Merck	Phase 2	35
Pembrolizumab + Lenvatinib	Merck	Phase 2	35
Avelumab	Merck	Phase 2	35
Pembrolizumab + Irinotecan + Paclitaxel	Merck	Phase 2	35
MK-0646	Merck	Phase 2	35